作者
Mark C Petrie, Subodh Verma, Kieran F Docherty, Silvio E Inzucchi, Inder Anand, Jan Bělohlávek, Michael Böhm, Chern-En Chiang, Vijay K Chopra, Rudolf A de Boer, Akshay S Desai, Mirta Diez, Jaroslaw Drozdz, Andre Dukát, Junbo Ge, Jonathan Howlett, Tzvetana Katova, Masafumi Kitakaze, Charlotta EA Ljungman, Béla Merkely, Jose C Nicolau, Eileen O'Meara, Pham Nguyen Vinh, Morten Schou, Sergey Tereshchenko, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, Per Johanson, Peter J Greasley, David Boulton, Olof Bengtsson, Pardeep S Jhund, John JV McMurray
发表日期
2020/4/14
期刊
Jama
卷号
323
期号
14
页码范围
1353-1368
出版商
American Medical Association
简介
Importance
Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes.
Objective
To evaluate the effects of dapagliflozin in patients with HFrEF with and without diabetes.
Design, Setting, and Participants
Exploratory analysis of a phase 3 randomized trial conducted at 410 sites in 20 countries. Patients with New York Heart Association classification II to IV with an ejection fraction less than or equal to 40% and elevated plasma N-terminal pro B-type natriuretic peptide were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019.
Interventions
Addition of once-daily 10 mg of dapagliflozin or placebo to recommended therapy.
Main Outcomes and Measures
The primary outcome was the composite of an episode of …
学术搜索中的文章
MC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand… - Jama, 2020